MP CARDIOFLOW-B (02160) News

MicroPort CardioFlow-B: Deferred Release of 2026 Interim Results

MicroPort CardioFlow Medtech Corporation - Class B (02160) announced that the release of its interim results and interim report for 2026 is expected to be delayed, as the Board of Directors believes the Company requires additional time to: (i) determine the background of the landlords and their related parties and their relationships with the Company; (ii) assess the commercial reasonableness of the lease terms, including but not limited to rent and security deposits; and (iii) evaluate the reasonableness of additional renovation costs related to the leases and their appropriate accounting treatment.

Sina HK StocksSep 1 09:14

MP CARDIOFLOW-B: INSIDE INFORMATIONDELAY IN PUBLICATION OF THE INTERIM RESULTSFOR THE SIX MONTHS ENDED JUNE 30, 2026;POSTPONEMENT OF DATE OF BOARD MEETING;ANDSUSPENSION OF TRADING

HKEXSep 1 08:56

MicroPort CardioFlow Medtech Corp. - Class B (02160) to suspend trading effective September 1

MicroPort CardioFlow Medtech Corporation - Class B (02160) announced that trading in its shares will be suspended with effect from 9:00 a.m. today (September 1, 2026).

Zhitong FinanceSep 1 08:55

MP CARDIOFLOW-B: POSTPONEMENT OF DATE OF BOARD MEETING

HKEXAug 26 22:58

MicroPort CardioFlow Medtech Corp. -B (02160) reported a total market value of HKD 440 million in deposited shares, with shareholders depositing 343 million shares to China Construction Bank (Asia).

On August 17, MicroPort CardioFlow Medtech Corp. -B (02160) experienced unusual movements in shareholdings, with the total market value of deposited shares amounting to HK$440 million, representing 26.97% of the total.

Zhitong FinanceAug 18 08:25

MP CARDIOFLOW-B: DATE OF BOARD MEETING

HKEXAug 14 18:42

HKEX Market Movement | MicroPort CardioFlow Medtech (02160.HK) Rises Nearly 5% on Expectation of First-Half Loss Not Exceeding USD 25 Million, with Global Cardiac Rhythm Management Business Continuing Steady Growth

MicroPort CardioFlower-B (02160) rose nearly 5%. As of this report, it was up 4.72% at HK$1.33, with a trading volume of HK$2.302 million.

Zhitong FinanceAug 12 11:55

MicroPort CardioFlow Sees Net Loss of Up to $25 Million in H1

MicroPort CardioFlow Medtech (HKG:2160) expects to record a net loss of no more than $25 million for the first half of 2026, according to a Tuesday filing with the Hong Kong Stock Exchange.The

MT NewswiresAug 12 11:22

Heartech Holdings Limited (02160.HK) issues profit warning: expected net loss for the interim period not to exceed USD 25 million

Gelonghui, August 11 — HeartCon Medical-B (02160.HK) announced that, as the Group completed the acquisition of the Cardiac Rhythm Management ("CRM") business (the "Acquisition") on December 19, 2025, the CRM business has been fully consolidated into the Group's financial statements for the first time for the six months ended June 30, 2026 (the "Reporting Period"). Based on a preliminary review of the Group’s unaudited consolidated management accounts for the Reporting Period and an assessment of the latest information currently available to the Board, the Group expects to report revenue of no less than USD 153 million and a net loss of no more than USD 25 million for the Reporting Period. During the Reporting Period, the Group

Gelonghui FinanceAug 11 22:16

MP CARDIOFLOW-B: RESULTS FORECAST FOR THE FIRST HALF OF 2026

HKEXAug 11 22:12

MicroPort Heartcare-B (02160): Shanghai MicroPort Heartcare entered into a lease agreement with Shanghai Huiqingcheng Investment Management.

MicroPort CardioFlow Medtech-B (02160) announced that, as of July 31, 2026 (after market close), its wholly-owned subsidiary Shanghai MicroPort CardioFlow entered into Lease Agreement I with the landlord, Shanghai Huiqingcheng Investment Management Co., Ltd., pursuant to which Shanghai MicroPort CardioFlow agreed to lease Property I from the landlord for a term of five years, commencing on August 1, 2026 and ending on July 31, 2031 (inclusive of both start and end dates).

Zhitong FinanceAug 2 20:04

Hong Kong Market Midday Commentary | Hang Seng Index Rises 0.81% at Midday, Xiaomi Up 7% Leads Gains Among Blue Chips

Xiaomi Group-W (01810) rose more than 7%, as the company announced that its Pengcheng launch event will be held on July 30, featuring the debut of two SUV models, the N90 and N70.

Zhitong FinanceJul 27 12:00

Hong Kong Stock Market Update | MicroPort Medisins-B (02160) Rises Over 13% as Two Core Products Gain Approval for Launch in Europe and Australia, Accelerating Global Expansion

MicroPort CardioFlow Medtech Corporation Limited (02160.HK) rose more than 13%. As of this report, it was up 13.33% at HK$1.19, with a trading volume of HK$1.8314 million.

Zhitong FinanceJul 27 10:59

Biopharmaceuticals: Innovation-driven industry trends are clear, with international expansion and commercial insurance offering breakthrough opportunities.

In the short term, healthcare cost containment and anti-corruption efforts in the medical sector have exerted some impact on healthcare demand, while innovative payment models, commercial insurance formularies, and off-hospital care settings may drive industry improvements. Although geopolitical tensions and shifts in liquidity have triggered a temporary pullback in the innovative drug sector and related industries, the long-term trends of innovation and international expansion remain clear, and the current correction presents medium- to long-term investment opportunities. In the second half of 2026, we continue to recommend a barbell strategy: one end focused on innovation and internationalization opportunities, and the other anchored by traditional, stable dividend-paying assets. The development trajectory of the innovative drug industry chain is clear, and order trends in the pharmaceutical supply chain remain robust. Despite short-term pressures on the innovative drug sector stemming from macroeconomic co

CICC InsightsJul 1 10:08

MicroPort HeartTech-B (02160) has a total custodied market value of HK$443 million, with company shareholders depositing 3.43 billion shares into Jianshe Asia.

On June 17, MicroPort CardioFlow Medtech (02160.HK) experienced unusual position activity, with a total on-deposit market value of HK$443 million, accounting for 26.97%.

Zhitong FinanceJun 18 08:15

MicroPort CardioFlow Grants 440,000 Share Options Under 2023 Incentive Scheme

TipRanksJun 4 21:37

MicroPort CardioFlow Wins Shareholder Backing for AGM Resolutions and Capital Mandates

TipRanksJun 4 21:13

MicroPort MedBot-B (02160): Junxiang Mao has been appointed as an Independent Non-Executive Director.

MicroPort CardioFlow Medtech Corporation-B (02160) announced that Ms. Xia Wu has resigned as a non-executive director, effective upon the conclusion of the annual general meeting of shareholders, and will not stand for re-election at the annual general meeting. Consequently, Ms. Wu ceased to be a member of the Company's Commercialization Committee (the Commercialization Committee), effective upon the conclusion of the annual general meeting of shareholders.

Zhitong FinanceJun 4 20:42

Japan Shares Rise on BOJ Rate Hike Expectations

Japanese shares ended higher on Wednesday after the OECD projected the Bank of Japan's (BOJ) policy rate could rise to 2% by the end of 2027, reinforcing expectations of a sustained monetary-

MT NewswiresMay 13 15:08

MicroPort CardioFlow Sets 2026 AGM, Seeks Fresh Share Buyback and Issuance Mandates

TipRanksMay 11 17:39